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Sex-Specific Outcomes for
HeartMate II
We read with great interest the recent paper by Starling et al.
(1), which provides results on the post-marketing study re-
quired by the Food and Drug Administration (FDA) as a
condition of approval of the HeartMate II (Thoratec Corpora-
tion, Pleasanton, California). However, the value of this report
would be strengthened considerably if the authors would
provide sex-specific data for the 38 women (22% of the patient
population) in the registry.
Although the FDA requires sex-specific data for all high-risk
device approvals, a recent analysis found that only 41% of recent
cardiovascular device Summaries of Safety and Effectiveness
Data reported such data (2). The HeartMate II was approved
based on data in just 44 women (3). Furthermore, the FDA’s
Summary of Safety and Effectiveness Data noted that women
had an 18% risk of stroke versus 6% in men and trends toward
greater bleeding and infection, although it was not possible to
make conclusions on differences in safety between men and
women (4). Therefore, the FDA specifically stated that the
required post-approval study (INTERMACS [Interagency
Registry for Mechanically Assisted Circulatory Support]) would
collect data on “gender-specific outcomes.” Given that sex-
specific outcomes was an FDA condition and that the device has
been specifically advertised as being suitable for women (5), we
believe the authors should report sex-specific results, which
would be particularly helpful for the outcomes in Figures 2 and
3 and adverse events in Table 3. Adequate sex-specific data will
help to clarify any differences in outcomes between men and
women (6) and enable better care of all patients with advanced
heart failure.
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Reply
On behalf of the authors, we thank Drs. Dhruva and Redberg for
their letter in reference to our paper (1). We strongly acknowledge
the importance that women are well represented in clinical trials
and that sex-specific outcomes are reported. Indeed, the newer
axial flow pumps have now enabled a wider dissemination of left
ventricular assist devices (LVADs), because prior devices were
limited to patients with body surface areas 1.5 m2. We reported
a consecutive group of patients implanted with the HeartMate II
(HMII) (Thoratec Corporation, Pleasanton, California) device
and the previously-approved Federal Drug Administration devices
as per a stipulated post-market approval study.
Of the 169 HMII patients, there were 131 men (78%) and 48
women (22%). The percentage of patients who were trans-
planted, recovered, or received ongoing support at 180 days was
90% for men and 92% for women. A smaller percentage of
women (24%) received transplants by 12 months of support
compared with men (39%), and a larger percentage were still on
LVAD support (63% women vs. 47% males) at 12 months.
However, there was no difference in overall survival (log rank
p  0.4038), and the 1-year survival estimate for patients
remaining on LVAD support was 83.8  6.7% (women) versus
88.3  3.0% (men). There were no statistically significant
differences in any adverse event between women and men. The
control group had a smaller percentage of women (17% vs.
22%), but this was not statistically significant (p  0.217). In
comparison with results in the clinical trial for bridge to
transplantation for the HeartMate II LVAD in 465 patients as
reported by Bogaev et al. (2), the distribution of women (22%)
and 361 men (78%) was the same. In addition, similar to the
post-approval study, there was a smaller percentage of women
receiving heart transplants over the first 18 months of support
and a greater percentage with ongoing support compared with
men, and also with no difference in overall survival. In contrast
to the post-approval study, in the clinical trial, hemorrhagic
stroke occurred more frequently in women versus men, and
device-related infections occurred less frequently than in men.
Finally, it should be noted that historically, the percentage of
women undergoing cardiac transplantation has been significantly
lower than men. The latest international heart transplant registry
report shows: men, 80.1% from 1992 to 2001 and 77.1% from
2002 to 2006/2009; p  0.0001 (3). We fully agree with Drs.
Dhruva and Redberg of the importance to collect and report
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respond and provide additional information.
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